These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34593018)

  • 21. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
    Takatani N; Kono Y; Beppu F; Okamatsu-Ogura Y; Yamano Y; Miyashita K; Hosokawa M
    Biochem Biophys Res Commun; 2020 Jul; 528(2):305-310. PubMed ID: 32475638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis.
    Siddiqui MS; Idowu MO; Parmar D; Borg BB; Denham D; Loo NM; Lazas D; Younes Z; Sanyal AJ
    Clin Gastroenterol Hepatol; 2021 Dec; 19(12):2670-2672. PubMed ID: 33152542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiretroviral drug-induced endothelial dysfunction is improved by dual PPARα/γ stimulation in obesity.
    Kamau F; Strijdom H; Mwangi P; Blackhurst D; Imperial E; Salie R
    Vascul Pharmacol; 2019 Oct; 121():106577. PubMed ID: 31284000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-NASH Drug Development Hitches a Lift on PPAR Agonism.
    Boeckmans J; Natale A; Rombaut M; Buyl K; Rogiers V; De Kock J; Vanhaecke T; M Rodrigues R
    Cells; 2019 Dec; 9(1):. PubMed ID: 31877771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of dual PPAR-α/γ agonist saroglitazar on diabetic retinopathy and oxygen-induced retinopathy.
    Joharapurkar A; Patel V; Kshirsagar S; Patel MS; Savsani H; Jain M
    Eur J Pharmacol; 2021 May; 899():174032. PubMed ID: 33753107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet.
    Giri SR; Bhoi B; Trivedi C; Rath A; Rathod R; Sharma A; Ranvir R; Kadam S; Ingale K; Patel H; Nyska A; Jain MR
    BMC Cancer; 2023 Jan; 23(1):59. PubMed ID: 36650455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages
    Lefere S; Puengel T; Hundertmark J; Penners C; Frank AK; Guillot A; de Muynck K; Heymann F; Adarbes V; Defrêne E; Estivalet C; Geerts A; Devisscher L; Wettstein G; Tacke F
    J Hepatol; 2020 Oct; 73(4):757-770. PubMed ID: 32360434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
    Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
    J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Staels B; Rubenstrunk A; Noel B; Rigou G; Delataille P; Millatt LJ; Baron M; Lucas A; Tailleux A; Hum DW; Ratziu V; Cariou B; Hanf R
    Hepatology; 2013 Dec; 58(6):1941-52. PubMed ID: 23703580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease.
    Tang Y; Bian Z; Zhao L; Liu Y; Liang S; Wang Q; Han X; Peng Y; Chen X; Shen L; Qiu D; Li Z; Ma X
    Clin Exp Immunol; 2011 Nov; 166(2):281-90. PubMed ID: 21985374
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet.
    Nagasawa T; Inada Y; Nakano S; Tamura T; Takahashi T; Maruyama K; Yamazaki Y; Kuroda J; Shibata N
    Eur J Pharmacol; 2006 Apr; 536(1-2):182-91. PubMed ID: 16574099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salsalate attenuates diet induced non-alcoholic steatohepatitis in mice by decreasing lipogenic and inflammatory processes.
    Liang W; Verschuren L; Mulder P; van der Hoorn JW; Verheij J; van Dam AD; Boon MR; Princen HM; Havekes LM; Kleemann R; van den Hoek AM
    Br J Pharmacol; 2015 Nov; 172(22):5293-305. PubMed ID: 26292849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure.
    Zaitone SA; Barakat BM; Bilasy SE; Fawzy MS; Abdelaziz EZ; Farag NE
    Naunyn Schmiedebergs Arch Pharmacol; 2015 Jun; 388(6):587-600. PubMed ID: 25708949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RLA8-A New and Highly Effective Quadruple PPAR-
    Li MH; Chen W; Wang LL; Sun JL; Zhou L; Shi YC; Wang CH; Zhong BH; Shi WG; Guo ZW
    J Pharmacol Exp Ther; 2019 Apr; 369(1):67-77. PubMed ID: 30745416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
    Cong WN; Tao RY; Tian JY; Liu GT; Ye F
    Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway.
    Zhang W; Wu R; Zhang F; Xu Y; Liu B; Yang Y; Zhou H; Wang L; Wan K; Xiao X; Zhang X
    Clin Exp Pharmacol Physiol; 2012 Dec; 39(12):1026-33. PubMed ID: 23127227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chaihu Guizhi Ganjiang Decoction attenuates nonalcoholic steatohepatitis by enhancing intestinal barrier integrity and ameliorating PPARα mediated lipotoxicity.
    Wu H; Lou T; Pan M; Wei Z; Yang X; Liu L; Feng M; Shi L; Qu B; Cong S; Chen K; Yang H; Liu J; Li Y; Jia Z; Xiao H
    J Ethnopharmacol; 2024 May; 326():117841. PubMed ID: 38310988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Combination of Blueberry Juice and Probiotics Ameliorate Non-Alcoholic Steatohepatitis (NASH) by Affecting SREBP-1c/PNPLA-3 Pathway via PPAR-α.
    Ren T; Zhu J; Zhu L; Cheng M
    Nutrients; 2017 Feb; 9(3):. PubMed ID: 28264426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alleviation of pulmonary fibrosis by the dual PPAR agonist saroglitazar and breast milk mesenchymal stem cells via modulating TGFß/SMAD pathway.
    Attia SH; Saadawy SF; El-Mahroky SM; Nageeb MM
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Aug; 397(8):5953-5974. PubMed ID: 38376539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.